Insulin Resistance Markers in Type 1 Diabetes Mellitus


Insulin resistance (IR) is a fundamental disorder of type 2 Diabetes Mellitus (DM), but it is also involved in the etiopathogenesis of type 1 DM, with important implications in the onset and progression of micro- and macrovascular complications in type 1 DM. Overweight plays the main role in the increased incidence of both types of DM, exacerbating IR. The epidemic increase of overweight and obesity makes it difficult to diagnose the exact phenotype of DM, as IR and autoimmunity often coexist. Many studies showed an increase in incidence of micro- and macrovascular complications in patients with type 1 DM with IR, compared to patients with type 1 DM without IR. The gold standard of IR evaluation is represented by the method of euglycemic-hyperinsulinemic clamp, applied on a reduced scale in research. Thus, it is necessary to identify early IR markers (clinical or biological markers), less laboured ones, that could be used on a large scale in current medical practice, for the IR determination in type 1 DM. Clinicians and health experts should prevent/ reduce the epidemic of overweight and obesity in young people, thus decreasing IR, and implicitly the chronic complications of DM.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Ionescu - Tîrgovişte C, Guja C, Brădescu O. Insulinorezistența obișnuită și cea severă. In: Tratat de diabet Paulescu. Ionescu - Tirgoviste C (ed). Publisher Romanian Academy Publishing House, Bucharest, pp 677-684, 2004.

  • 2. Olefsky JM, Kruszynska YT. Insulin resistance. In Ellenberg and Rifkin’s Diabetes Mellitus 6th edition. Porte DJ, Sherwin RS, Baron A (ed). Eds. McGraw-Hill, New York, pp 367-400, 2003.

  • 3. Rosenbloom AL. Obesity, insulin resistance, β- cell autoimmunity and the changing clinical epidemiology of childhood diabetes. Diabetes Care 26: 2954-2956, 2003.

  • 4. Chillarón JJ, Goday A, Flores-Le-Roux JA et al. Estimated glucose disposal rate in assessment of the metabolic syndrome and microvascular complications in patients with type 1 diabetes. J Clin Endocrinol Metab 94: 3530-4, 2009.

  • 5. Duvnjak L, Kokić V, Bulum T, Kokić S, Krnić M, Hozo IS. The metabolic syndrome is associated with high-normal urinary albumin excretion and retinopathy in normoalbuminuric type 1 diabetic patients. Coll Antropol 36: 1373- 8, 2012.

  • 6. Șerban V, Sima A. Insulinorezistența în diabetul zaharat tip 1. In: Tratat Român de boli metabolice. Serban V (ed). Brumar Publisher, Timișoara, pp 167-171, 2010.

  • 7. Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for type I as well as type II diabetes. Int J Obes 33: 716-726, 2009.

  • 8. Wilkin T J. The accelerator hypothesis: weight gain as the missing link between Type I and Type II diabetes. Diabetologia 44: 914-922, 2001.

  • 9. Mottl AK, Lauer A, Dabelea D et al. Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetes. Diabetes Care 36: 3633-8, 2013.

  • 10. Tripathi A, Rizvi AA, Knight LM, Jerrell JM. Prevalence and impact of initial misclassification of pediatric type 1 diabetes mellitus. South Med J 105: 513-517, 2012.

  • 11. Liu LL, Lawrence JM, Davis C et al. SEARCH for Diabetes in Youth Study Group. Prevalence of overweight and obesity in youth with diabetes in USA: the SEARCH for Diabetes in Youth study. Pediatr Diabetes 11: 4-11, 2010.

  • 12. Shaw J. Epidemiology of childhood type 2 diabetes and obesity. Pediatr Diabetes 8: 7-15, 2007.

  • 13. Fu JF, Liang L, Zou CC et al. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes 31: 15-22, 2007.

  • 14. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes Care 30: 1248-54, 2007.

  • 15. Timar R, Timar B, Degeratu D, Serafinceanu C, Oancea C. Metabolic syndrome, adiponectin and proinflammatory status in patients with type 1 diabetes mellitus. J Int Med Res 0: 1-8, 2014.

  • 16. Clenciu D, Vladu M, Gîrgavu S et al. Metabolic syndrome in patients with T1DM older than 10 years. Rom J Diab Nutr Metab Dis 18: 207-210, 2011.

  • 17. Greenbaum CJ. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 18: 192-200, 2002.

  • 18. Pagano G, Tagliaferro V, Carta Q et al. Metformin reduces insulin requirement in type 1 (insulindependent) diabetes. Diabetologia 24: 351-354, 1983.

  • 19. Gin H, Messerchmitt C, Brottier E, Aubertin J. Metformin improved insulin resistance in type I, insulindependent, diabetic patients. Metab Clin Exp 34: 923-925, 1985.

  • 20. Pang T T L, Narendran P. Addressing insulin resistance in Type 1 diabetes. Diabet Med 25: 1015-1024, 2008.

  • 21. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diabetes Care 30: 707-712, 2007.

  • 22. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62: 963-970, 2002.

  • 23. Teupe B, Bergis K. Epidemiological evidence for “double diabetes.” Lancet 337: 361-362, 1991.

  • 24. Olson JC, Erbey JR, Williams KV et al. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann Epidemiol 12: 331-337, 2002.

  • 25. Alberti KG, Zimmet P, Shaw J et al. The metabolic syndrome - a new worldwide definition. Lancet 366: 1059-62, 2005.

  • 26. Dabelea D, D’Agostino Jr RB, Mason CC et al. Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 54: 78-86, 2011.

  • 27. Pănuş C, Moța M. Obezitatea. In: Patologia nutrițional metabolică. Moța M, Dincă M (ed). Publisher Medical University Craiova, pp 85- 124, 2010.

  • 28. World Health Organization. Waist circumference and waist-hip ratio. Report of a WHO expert consultation, Geneva, 2008. Accessed on 15 January 2015 at: publications/obesity/WHO_report_waistcircumference_an d_waisthip_ratio/en

  • 29. Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ. Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49: 626-632, 2000.

  • 30. Hsieh SD, Yoshinaga H, Muto T. Waist-toheight ratio, a simple and practical index for assessing central fat distribution and metabolic risk in Japanese men and women. Int J Obes 27: 610-616, 2003.

  • 31. Holman R, Hines G, Kennedy I, Stevens R, Matthews D, Levy J. A calculator for HOMA. Diabetologia 47[Suppl 1]: A222, 2004. (abstract)

  • 32. Li X, Zhou ZG, Qi HY, Chen XY, Huang G. Replacement of insulin by fasting C-peptide in modified homeostasis model assessment to evaluate insulin resistance and islet beta cell function. Zhong Nan Da Xue Xue Bao Yi Xue Ban 29: 419-423, 2004.

  • 33. Constantin C, Cheța D. Proinsulina și peptidul C. In: Tratat Român de boli metabolice. Șerban V (ed), Brumar Publisher, Timișoara, pp 119-123, 2010.

  • 34. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 17: 181-189, 2000.

  • 35. Patel N, Taveira TH, Choudhary G, Whitlatch H, Wu WC. Fasting serum C-peptide levels predict cardiovascular and overall death in nondiabetic adults. J Am Heart Assoc 1: e003152, 2012.

  • 36. Abdullah A, Hasan H, Raigangar V, Bani-Issa W. C-Peptide versus insulin: relationships with risk biomarkers of cardiovascular disease in metabolic syndrome in young arab females. Int J Endocrinol 2012:420792, 2012. Accessed at:

  • 37. Ohkura T, Shiochi H, Fujioka Y et al. 20/(fasting C-peptide × fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol 12: 21, 2013.

  • 38. Iwata M, Maeda S, Kamura Y et al. Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 35: 1763-1770, 2012.

  • 39. Anderwald C, Anderwald-Stadler M, Promintzer M et al. The Clamp-Like Index: a novel and highly sensitive insulin sensitivity index to calculate hyperinsulinemic clamp glucose infusion rates from oral glucose tolerance tests in nondiabetic subjects. Diabetes Care 30: 2374-2380, 2007.

  • 40. Laurie Barclay. Triglycerides and TG-HDL ratio help identify insulin resistance in overweight patients. Intern Med 139: 802-809, 2003.

  • 41. Chiang JK, Lai NS, Chang JK, Koo M. Predicting insulin resistance using the triglyceride-to-highdensity lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc Diabetol 10: 93, 2011.

  • 42. Hadjadj S, Duly-Bouhanick B, Bekherraz A et al. Serum triglycerides are a predictive factor for the development and the progression of renal and retinal complications in patients with type 1 diabetes. Diabetes Metab 30: 43-51, 2004.

  • 43. Moța M, Vladu D. Obezitatea. In: Diabet zaharat, Nutriție, Boli metabolice. Compendiu. Moța M (ed). Publisher Medical University Craiova, pp 230-261, 2001.

  • 44. Danielson KK, Drum ML, Estrada CL, Lipton RB. Racial and ethnic differences in an estimated measure of insulin resistance among individuals with type 1 diabetes. Diabetes Care 33: 614-619, 2010.

  • 45. Epstein EJ, Osman JL, Cohen HW, Rajpathak SN, Lewis O, Crandall JP. Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes. Diabetes Care 36: 2280-5, 2013.

  • 46. Bulum T, Duvnjak L, Prkacin I. Estimated glucose disposal rate in assessment of renal function in patients with type 1 diabetes. Coll Antropol 36: 459-465, 2012.

  • 47. Costacou T, Chang Y, Ferrell RE, Orchard TJ. Identifying genetic susceptibilities to diabetes-related complications among individuals at low risk of complications: an application of tree-structured survival analysis. Am J Epidemiol 164: 862-872, 2006.

  • 48. Palomo Atance E, Ballester Herrera MJ, Giralt Muiña P, Ruiz Cano R, León Martín A, Giralt Muiña J. Estimated glucose disposal rate in patients under 18 years of age with type 1 diabetes mellitus and overweight or obesity. Endocrinol Nutr 60: 379-385, 2013.

  • 49. Donga E, van Dijk M, van Dijk JG et al. Partial sleep restriction decreases insulin sensitivity in type 1 diabetes. Diabetes Care 33: 1573-7, 2010.

  • 50. Bulum T, Duvnjak L. Insulin resistance in patients with type 1 diabetes: relationship with metabolic and inflammatory parameters. Acta Clin Croat 52: 43-51, 2013.


Journal + Issues